Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PBI-4547 in Healthy Subjects
NCT04068259Phase 1Terminated
- Sponsor
- Liminal BioSciences Inc.
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PBI-4547 in Nonalcoholic steatohepatitis (NASH) and Liver Fibrosis (LF) (5 cohorts), sponsored by Liminal BioSciences Inc. Primary endpoints: Treatment-Emergent Adverse Events, Clinically Significant Laboratory Evaluation Findings and 3 more. Started Sep 2019; status: terminated.
02
Drugs
PBI-4547
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT04068259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068259.